Brentuximab vedotin treatment for mycosis fungoides with CD30+ large‐cell transformation in the early stage
In this paper, we bring hope to patients with mycosis fungoides (MF) with CD30+ large‐cell transformation (LCT), which is often a histological marker of poor prognosis and is associated with a mean 5‐year survival of <20%. Although skin biopsy is a painful procedure, it is the only test for early...
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Frontiers Media S.A.
2023-12-01
|
| Reeks: | Journal of Cutaneous Immunology and Allergy |
| Online toegang: | https://doi.org/10.1002/cia2.12330 |